ALKEM2020-07-012020-09-30in-bse-fin:OneOperatingExpenses01Member ALKEM2020-07-012020-09-30in-bse-fin:FourOperatingExpenses01Member ALKEM2020-07-012020-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ALKEM2020-07-012020-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ALKEM2020-07-012020-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member ALKEM2020-07-012020-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares ALKEM 2020-04-01 2021-03-31 2020-10-28 INR Millions Half yearly true Cash Flow Indirect Single segment The Company is exclusively engaged in pharmaceutical business 2020-07-01 2020-09-30 Unaudited Consolidated 23628000000.00 355400000.00 23983400000.00 4736900000.00 3680800000.00 921700000.00 4080100000.00 180400000.00 702400000.00 4203600000.00 18505900000.00 5477500000.00 0.00 5477500000.00 1141900000.00 -479500000.00 662400000.00 0.00 4815100000.00 0.00 0.00 0.00 0.00 4815100000.00 -236320000.00 4578780000.00 4720612000.00 94488000.00 4482792000.00 95988000.00 239100000.00 2 39.48 39.48 0.00 0.00 39.48 39.48 1. The above unaudited consolidated financial results were reviewed and recommended by the Audit Committee on 5 November 2020 and subsequently approved by the Board of Directors at its meeting held on 6 November 2020. The auditors have issued an unmodified report on the financial results for the quarter and six months ended 30 September 2020. n n2. The Group has considered internal and external information while assessing recoverability of its assets upto the date of approval of these financial results by the Board of Directors. Based on such assessment and considering the current economic indicators, the Group expects to recover the carrying amount of these assets. The Board of Directors has also considered the impact of COVID-19 on the business for the foreseeable future and have concluded that the Group has sufficient resources to continue as a going concern. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Group will continue to closely monitor any material changes to future economic conditions. n n3. During the quarter ended 30 September 2020, the Company has paid a final dividend of Rs. 3 (Rupees three only) per equity share (150% on the face value of Rs. 2 each) for the financial year 2019-20. n n4. The Group operates in one reportable business segment i.e. Pharmaceuticals , accordingly no separate disclosure of segment has been made. Single segment 2020-04-01 2020-09-30 Unaudited Consolidated 43662900000.00 790400000.00 44453300000.00 10123600000.00 7149000000.00 -594600000.00 8022400000.00 351400000.00 1370700000.00 7625800000.00 34048300000.00 10405000000.00 0.00 10405000000.00 2142500000.00 -784500000.00 1358000000.00 0.00 9047000000.00 0.00 0.00 0.00 0.00 9047000000.00 -222220000.00 8824780000.00 8940712000.00 106288000.00 8717892000.00 106888000.00 239100000.00 2 74.78 74.78 0.00 0.00 74.78 74.78 Other expenses 4203600000.00 Other expenses 7625800000.00 351359000.00 -1697982000.00 -229558000.00 0.00 -280281000.00 0.00 0.00 0.00 0.00 -1038324000.00 0.00 0.00 0.00 1370711000.00 0.00 625165000.00 0.00 0.00 0.00 140640000.00 -82000.00 407494000.00 0.00 0.00 0.00 0.00 37803000.00 0.00 0.00 -1127879000.00 9277121000.00 0.00 0.00 0.00 1520227000.00 0.00 7756894000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5927000.00 676722000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3371000.00 0.00 0.00 0.00 0.00 0.00 82000.00 318285000.00 0.00 -4989960000.00 0.00 -5339017000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1699843000.00 0.00 101892000.00 358700000.00 296750000.00 0.00 0.00 -2457185000.00 -39308000.00 5526000.00 -33782000.00 1759350000.00 1725568000.00